Find, compare & contact
Verinurad
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Verinurad API 1352792-74-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Verinurad. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Verinurad
- Synonyms:
- Cas Number:
- 1352792-74-5
- DrugBank number:
- DB11873
- Unique Ingredient Identifier:
- 12WJ62D047
General Description:
Verinurad, identified by CAS number 1352792-74-5, is a notable compound with significant therapeutic applications. Verinurad has been used in trials studying the basic science and treatment of Gout, Gout and Hyperuricemia, and Gout and Asymptomatic Hyperuricemia.
Classification:
Verinurad belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings, classified under the direct parent group Naphthalenes. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Naphthalenes class, specifically within the None subclass.
Categories:
Verinurad is categorized under the following therapeutic classes: Acids, Acyclic, Antigout Preparations, Antirheumatic Agents, Fatty Acids, Fatty Acids, Volatile, Lipids. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Verinurad is a type of Anti-Gout
The Anti-Gout category of pharmaceutical active pharmaceutical ingredients (APIs) consists of medications specifically designed to alleviate the symptoms and treat the underlying causes of gout, a common type of arthritis. Gout occurs due to the accumulation of uric acid crystals in the joints, leading to severe pain, inflammation, and swelling.
Anti-Gout APIs primarily target the management of uric acid levels in the body. These APIs include medications such as allopurinol, febuxostat, probenecid, and colchicine. Allopurinol and febuxostat work by inhibiting an enzyme called xanthine oxidase, which is involved in the production of uric acid. Probenecid, on the other hand, enhances the excretion of uric acid from the body by blocking its reabsorption in the kidneys. Colchicine is commonly used to reduce pain and inflammation during gout attacks.
The effectiveness of Anti-Gout APIs in managing gout symptoms and preventing recurrent episodes has made them crucial in the treatment regimen for gout patients. These APIs are typically formulated into oral tablets or capsules for easy administration. The dosage and duration of treatment may vary depending on the severity of the condition and the individual's response to therapy.
It is important to note that the use of Anti-Gout APIs should be guided by healthcare professionals to ensure proper dosing and monitoring of potential side effects. Gout patients are advised to follow a balanced diet, limit the consumption of foods high in purines (which can increase uric acid levels), and maintain a healthy lifestyle to complement the pharmacological treatment.
In conclusion, Anti-Gout APIs play a vital role in managing gout, reducing pain and inflammation, and regulating uric acid levels. These medications provide significant relief to individuals suffering from gout, helping them lead a more comfortable and active life.
